These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32790003)

  • 1. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change.
    Nogueira M; Warren RB; Torres T
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):824-834. PubMed ID: 32790003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review.
    Fowler E; Ghamrawi RI; Ghiam N; Liao W; Wu JJ
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1449-1456. PubMed ID: 32012384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.
    Torres T; Chiricozzi A; Puig L; Lé AM; Marzano AV; Dapavo P; Dauden E; Carrascosa JM; Lazaridou E; Duarte G; Carvalho AVE; Romiti R; Rompoti N; Teixeira L; Abreu M; Ippoliti E; Maronese CA; Llamas-Velasco M; Vilarrasa E; Del Alcázar E; Daponte AI; Papoutsaki M; Carugno A; Bellinato F; Gisondi P
    Am J Clin Dermatol; 2024 Mar; 25(2):333-342. PubMed ID: 38265746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy.
    Mastorino L; Dapavo P; Trunfio M; Avallone G; Rubatto M; Calcagno A; Ribero S; Quaglino P
    Acta Derm Venereol; 2022 Nov; 102():adv00821. PubMed ID: 36065745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.
    Sauzullo I; Mengoni F; Marocco R; Potenza C; Skroza N; Tieghi T; Lichtner M; Vullo V; Mastroianni CM
    Br J Dermatol; 2013 Nov; 169(5):1133-40. PubMed ID: 23909256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberculosis and interleukin blocking monoclonal antibodies: Is there risk?
    Kelsey A; Chirch LM; Payette MJ
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of tuberculosis with anti-tumor necrosis factor-alpha therapy in patients with psoriasis and psoriatic arthritis in Indian population.
    Sarkar S; Panda S; Kim B; Raychaudhuri SK; Ghosh A; Raychaudhuri SP
    Indian J Dermatol Venereol Leprol; 2020; 86(1):1-7. PubMed ID: 31719235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection.
    Megna M; Patruno C; Bongiorno MR; Gambardella A; Guarneri C; Foti C; Lembo S; Loconsole F; Fabbrocini G
    J Dermatolog Treat; 2022 Aug; 33(5):2629-2633. PubMed ID: 35385362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
    Akyuz F; Cavus B; Iliaz R; Soyer OM; Ormeci A; Evirgen S; Onder S; Koksalan K; Keskin M; Karaca C; Demir K; Gulluoglu M; Cagatay T; Besisik F; Kaymakoglu S
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):777-780. PubMed ID: 30964811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberculosis reactivation risk in dermatology.
    Pescitelli L; Ricceri F; Prignano F
    J Rheumatol Suppl; 2014 May; 91():65-70. PubMed ID: 24789002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.
    Doherty SD; Van Voorhees A; Lebwohl MG; Korman NJ; Young MS; Hsu S; National Psoriasis Foundation
    J Am Acad Dermatol; 2008 Aug; 59(2):209-17. PubMed ID: 18485527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer.
    Bordignon V; Bultrini S; Prignano G; Sperduti I; Piperno G; Bonifati C; Filippetti M; Toma L; Latini A; Di Cecio M; Giuliani A; Vocaturo A; Trento E; D' Agosto G; Francesconi F; Cataldo A; Vento A; Cilenti V; Berardesca E; Ameglio F; Cordiali Fei P; Ensoli F
    J Biol Regul Homeost Agents; 2011; 25(2):213-20. PubMed ID: 21880210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients.
    Sánchez-Moya AI; Dauden E
    J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):730-3. PubMed ID: 21564322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China.
    Li CR; Mao QX; Chen M; Jia WX; Yao X; Feng SY; Jia H; Gong JQ; Yang XY
    Drug Des Devel Ther; 2015; 9():5591-4. PubMed ID: 26508833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the use of the interferon-γ response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-α therapy: a prospective head-to-head cross-sectional study.
    Martyn-Simmons CL; Mee JB; Kirkham BW; Groves RW; Milburn HJ
    Br J Dermatol; 2013 May; 168(5):1012-8. PubMed ID: 23278714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
    Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
    J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor.
    Robert M; Miossec P
    Cell Mol Immunol; 2021 Jul; 18(7):1644-1651. PubMed ID: 34021269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.
    Puig L; Tsai TF; Bhutani T; Uy J; Ramachandran P; Song M; You Y; Gooderham M; Lebwohl M
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1744-1749. PubMed ID: 32289190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate type 1 immune response, but not IL-17 cells control tuberculosis infection.
    Segueni N; Jacobs M; Ryffel B
    Biomed J; 2021 Apr; 44(2):165-171. PubMed ID: 32798210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.